Keytruda is immunotherapy, not chemotherapy. The drug, known generically as pembrolizumab, belongs to a class called PD-1 checkpoint inhibitors. Those medicines train your immune system to recognize and destroy cancer cells, rather than poisoning the cells directly. That single distinction shapes almost everything about treatment, including side effects, monitoring timelines, and the tumor tests your oncologist runs before offering it.
This guide explains what sets immunotherapy apart from chemo, how Keytruda works inside the body, the cancers it is approved for, and the side effects unique to PD-1 inhibitors. It is written for patients and family members who want clear answers before the next oncology visit.
Keytruda Is Immunotherapy, Not Chemotherapy
Keytruda (pembrolizumab) is a humanized monoclonal antibody classified as a PD-1 checkpoint inhibitor, a type of cancer immunotherapy. The FDA first approved it in 2014 for advanced melanoma, and the label has since expanded to more than a dozen tumor types. Chemo drugs attack rapidly dividing cells, but pembrolizumab blocks a protein on immune T cells, releasing a natural brake so those T cells can find and destroy cancer.
Think of chemotherapy as a sledgehammer aimed at the tumor, and Keytruda as a system that removes the blindfold from your body’s own security forces. Your immune system already had the tools; the drug simply lets it use them.
That distinction is not a small one. It explains why the side effect profile, the timeline for results, and the eligibility testing all look different from chemo. Your oncologist chose Keytruda (or is considering it) because the mechanism matches a specific feature of your tumor, and the next sections break down what that means in practice for you.
What Sets Immunotherapy Apart From Chemotherapy
Chemotherapy drugs are cytotoxic, meaning they damage or kill cells that divide quickly. Cancer cells divide quickly, but so do your hair follicles, the lining of your mouth, and your bone marrow. That overlap is why classic chemo side effects include hair loss, mouth sores, nausea, and low blood counts. Immunotherapy drugs like Keytruda take a fundamentally different route. They do not directly attack cancer cells.
Instead, they modulate your immune system’s response so it can recognize tumors it was previously ignoring.
Why the Side Effect Lists Look So Different
Because immunotherapy activates immune cells, the side effects come from an overactive immune system rather than from cell damage. These reactions are called immune-related adverse events (irAEs), and they can affect almost any organ in your body. Common sites include the skin (rashes, itching), the colon (diarrhea, colitis), the lungs (cough, pneumonitis), the liver (elevated liver enzymes), and the endocrine glands (thyroid problems, adrenal issues).
Hair loss and severe nausea are far less common with PD-1 inhibitors than with cytotoxic chemo, though they are not impossible.
Combination Therapy Is Why the Confusion Is So Common
Keytruda is approved for several cancers as a stand-alone treatment, but it is also approved alongside platinum-based chemotherapy combinations for cancers like metastatic non-small cell lung cancer. When you receive both at the same infusion center, on the same day, the labels blur. The two approaches are genuinely complementary: chemo can release tumor antigens that help your immune system respond, while pembrolizumab keeps that response active.
| Feature | Traditional Chemotherapy | Keytruda (Pembrolizumab) |
|---|---|---|
| Drug class | Cytotoxic agents (various classes) | PD-1 checkpoint inhibitor (monoclonal antibody) |
| Mechanism | Directly damages dividing cells | Releases the brake on immune T cells |
| Typical side effects | Hair loss, nausea, low blood counts, mouth sores, fatigue | Rash, colitis, pneumonitis, thyroid dysfunction, hepatitis |
| Onset of side effects | Often within days to weeks of a cycle | Can appear weeks to months after starting, sometimes after stopping |
| Administration | Oral pills, IV infusions, or injected | IV infusion, typically every 3 or 6 weeks |
| Biomarker testing | Not always required | Often requires PD-L1, MSI, or TMB testing on tumor tissue |
How Keytruda Works Inside the Body
PD-1 is a receptor on the surface of T cells, the white blood cells that coordinate immune attacks. When PD-1 binds to a partner protein called PD-L1, the T cell essentially receives a “stand down” signal. Many tumors hijack this system by expressing PD-L1 on their own surface, which tells passing T cells to leave them alone.
Keytruda is a monoclonal antibody designed to bind PD-1 directly, blocking that handshake so the T cell stays in attack mode. The result is an immune response that can shrink tumors, hold them stable, or in some cases eliminate detectable disease.
Why Biomarker Testing Often Comes First
Oncologists usually order tests on your tumor biopsy before starting Keytruda. The most common biomarker is PD-L1 expression, measured as a percentage of tumor cells or immune cells staining positive. Higher PD-L1 levels often predict a stronger response, though responses can still occur at lower levels depending on your cancer type.
Two other biomarkers matter: microsatellite instability (MSI) or mismatch repair deficiency (dMMR), which indicate a high number of DNA errors your immune system can recognize, and tumor mutational burden (TMB), which counts how many mutations sit inside the cancer genome. Cancers with high MSI or high TMB tend to respond more reliably to PD-1 blockade, regardless of where they originated in your body.
If your care team mentions a “tissue sample going to the lab for staining,” PD-L1 testing is often what is happening behind the scenes. Ask for the report and the percentage if it is available, because it directly shapes whether Keytruda is offered to you as a stand-alone option or combined with chemo.
Cancers Keytruda Is Approved to Treat
The list of FDA-approved indications for pembrolizumab has expanded steadily since 2014, and it now covers more than a dozen cancer types plus a tissue-agnostic approval for any MSI-high or dMMR solid tumor.
Common approvals include advanced melanoma, non-small cell lung cancer (both as a stand-alone option in PD-L1-high disease and combined with chemo in broader populations), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial (bladder) cancer, renal cell carcinoma, triple-negative breast cancer (combined with chemo), certain gastric and esophageal cancers, cervical cancer, hepatocellular carcinoma, and Merkel cell carcinoma.
Tumor Biology Drives Eligibility, Not Just the Diagnosis
Two patients with the same cancer type can receive very different treatment plans, because the FDA approvals for Keytruda are often tied to specific biomarker thresholds. A non-small cell lung cancer with PD-L1 expression above 50% may qualify for pembrolizumab alone, while the same cancer with PD-L1 below 1% might require a chemo combination to reach the approval criteria.
An MSI-high colorectal tumor can receive Keytruda based on that biomarker alone, whereas an MSI-stable colorectal tumor typically cannot. Approval lists are worth checking against your specific situation, because the marketing materials you see in the waiting room tend to highlight the broadest scenarios.
- Melanoma: First PD-1 approval in 2014, now used in both advanced and adjuvant settings after surgery.
- Non-small cell lung cancer: Used alone for high PD-L1 tumors, or combined with platinum chemo for broader populations.
- Head and neck squamous cell carcinoma: Approved for recurrent or metastatic disease, often after platinum chemotherapy.
- Classical Hodgkin lymphoma: Used after failure of prior therapies, where responses can be durable.
- Urothelial (bladder) cancer: Approved for certain patients with locally advanced or metastatic disease.
- MSI-high or dMMR solid tumors: A tissue-agnostic approval covering any cancer type with these features.
Side Effects Unique to Keytruda Compared With Chemo
Keytruda’s side effect profile is the most concrete way to feel the difference between immunotherapy and chemotherapy in your own body. Chemo side effects are tied to direct cell damage, so they tend to show up predictably after each cycle and resolve in a recognizable pattern.
Immunotherapy side effects are tied to an activated immune system mistakenly attacking your healthy tissue, so they can appear at almost any point, even months after treatment has ended, and they often look like autoimmune conditions.
Immune-Related Adverse Events to Watch For
Any new symptom that starts after you begin Keytruda deserves a call to your care team, even if it seems minor. Mild diarrhea can be the first sign of colitis. A dry cough or new shortness of breath can signal pneumonitis, a lung inflammation that needs prompt steroid treatment. A rash, especially with itching, can herald skin-directed immune activity.
Fatigue, joint pain, and headaches can point to thyroid or adrenal dysfunction, which is detected through routine bloodwork rather than obvious symptoms. The key rule is that early reporting leads to faster treatment, often with corticosteroids, and most immune side effects resolve when caught in time.
Why Oncologists Coach You to Report Symptoms Right Away
Severe immune-related side effects are uncommon, but they can become dangerous if missed. Colitis can lead to bowel perforation. Pneumonitis can progress to respiratory failure. Hepatitis can quietly elevate liver enzymes until they reach critical levels. The good news is that almost all of these are reversible with the right intervention, and the most common immune side effects (mild skin rash, mild thyroid changes) are usually managed without stopping treatment entirely.
Your oncology nurse is trained to triage these calls; the threshold for calling is much lower than it would be for a healthy person.
| Body System | Chemotherapy Side Effect | Keytruda (Immunotherapy) Side Effect |
|---|---|---|
| Skin | Hair loss, nail changes | Rash, itching, vitiligo, rare severe skin reactions |
| Gut | Nausea, vomiting, mouth sores | Diarrhea, colitis, rare bowel inflammation |
| Blood counts | Low white cells, anemia, low platelets | Rare cytopenias, more often inflammatory than suppressive |
| Lungs | Less common as direct toxicity | Pneumonitis (cough, shortness of breath) |
| Endocrine | Uncommon | Thyroid dysfunction, adrenal insufficiency, hypophysitis |
| Liver | Elevated enzymes from drug toxicity | Hepatitis from immune activation |
Questions Worth Bringing to Your Oncologist
Appointments move quickly, and the language around cancer treatment is dense even for professionals. Walking in with a short written list turns a confusing visit into a working conversation. These questions are the ones that consistently change the shape of a treatment plan, because they surface the details that determine your eligibility, side effect expectations, and what to watch for at home.
- Biomarker status: Has your tumor been tested for PD-L1, MSI, dMMR, or TMB, and what did the results show?
- Treatment goal: Is Keytruda being given to try to cure, to control growth long-term, or to shrink the cancer before another treatment step?
- Combination plan: If chemo is included, which drugs, how many cycles, and what happens after the chemo portion ends?
- Infusion schedule: How often will you receive infusions, and how long is each visit including observation time?
- Side effect triage: Which symptoms should trigger an immediate call, and which can wait until your next scheduled visit?
- Imaging plan: How often will your scans be repeated, and at what point will the team decide whether the drug is working?
- Other medications: Are there any prescription drugs, supplements, or vaccines you should avoid while on treatment?
Bring a small notebook or use your phone’s notes app during the visit. Oncology information is delivered fast, and the details that matter most are the ones you will want to revisit when you get home.
The Bottom Line
Keytruda is a PD-1 checkpoint inhibitor, a form of immunotherapy that works by releasing the natural brakes on your immune system so it can attack cancer. It is not chemotherapy, and the side effects, eligibility testing, and timelines reflect that difference. The fastest way to feel less lost is to anchor on the mechanism: chemo damages dividing cells, Keytruda lifts a blindfold from your T cells, and your body does the rest.
FAQ
Is Keytruda considered chemotherapy?
No. Keytruda (pembrolizumab) is a form of immunotherapy, specifically a PD-1 checkpoint inhibitor. It does not poison cancer cells the way cytotoxic chemotherapy does, and it is classified in a completely different drug class even when given alongside chemo in a combination regimen.
What kind of treatment is Keytruda immunotherapy?
Keytruda is a monoclonal antibody that targets the PD-1 receptor on T cells, blocking the signal tumors use to hide from your immune system. It is part of a broader category called immune checkpoint inhibitors, which also includes drugs like nivolumab and atezolizumab.
Why is Keytruda called immunotherapy instead of chemotherapy?
Because it works by activating your own immune system to fight cancer rather than directly killing cancer cells. Immunotherapy and chemotherapy are categorized by mechanism of action, and the mechanism here is immune modulation, not cytotoxicity.
How does pembrolizumab work in the body?
Pembrolizumab binds to the PD-1 protein on T cells, preventing tumors from sending a “stand down” signal through PD-L1. With that brake released, your T cells can recognize and attack cancer cells they previously ignored.
Can Keytruda be used with chemotherapy?
Yes. Keytruda is approved in combination with platinum-based chemotherapy for several cancers, including certain non-small cell lung cancers and triple-negative breast cancer. The two approaches can work together because chemo releases tumor antigens that may strengthen the immune response Keytruda enables.
What side effects should you watch for while on Keytruda?
Cough or shortness of breath, persistent diarrhea, yellowing of the skin or eyes, severe rash, and unusual fatigue or headaches are all worth reporting right away. These can be signs of immune-related side effects that are usually manageable when caught early.
